John Lindsay Marshall, MD, sheds light on the significance of the FDA approval of fruquintinib for patients with heavily pretreated metastatic colorectal cancer and discusses the efficacy and safety data from the FRESCO and FRESCO-2 trials that supported the decision in this population.
The FDA has granted priority review to the new drug application seeking the approval of fruquintinib for use in the treatment of adult patients with previously treated metastatic colorectal cancer.
from a complaint. is the white house afraid that this president may get pulled in about some as this heats up over the summer and fall, may get pulled into this? reporter: can i tell you, the way they ve handled the illinois political situation, there s been this fear of touching it, right? there s this assumption since blagojevich tried to sell the seat, figure illinois-related is radioactive. for instance, they made one effort to find a candidate in that senate race, it failed. then they backed off. even though you talked about the democratic nominee, alexei, his family bank that just went under. he s also going to get potentially dragged into the resco trial, another part of this blagojevich situation. obama is? reporter: well, no, this is ginnoulis. so it s not to say, there are been questions, why didn t this white house with david axelrod and barack obama, why didn t they try to wash their hands of it when they were going to get